Here, we examined whether an inhibition of CD47-SIRPα axis, by either a genetic disruption or by using an antagonistic agent for SIRPα, allows neutrophils to more efficiently kill dinutuximab-opsonized neuroblastoma cells in vitro. Here, SIRPA is linked to neuroblastoma.